Skip to main content

Year: 2019

Heijmans ontwikkelt en realiseert 144 woningen in Utrecht

Heijmans heeft opdracht gekregen van de gemeente Utrecht om 144 koopwoningen te ontwikkelen en realiseren in Leidsche Rijn Centrum. De gemeente gunde de opdracht vanwege de onderscheidende architectuur en manier waarop Heijmans een variëteit aan woningen, duurzaamheid en groen combineert in het project. Het project Bellevue heeft een waarde van circa €55 miljoen.Bellevue draagt bij aan het beantwoorden van de grote vraag naar woningen binnen de gemeente Utrecht in verschillende prijscategorieën. In het project zet Heijmans vol in op het creëren van een gezonde woon- en leefomgeving voor uiteenlopende doelgroepen. Zo worden de woningen zeer energiezuinig en kunnen bewoners gebruikmaken van elektrische deelvoertuigen. Ook komen er verschillende binnentuinen waar bewoners elkaar kunnen ontmoeten. Bellevue wordt naast de Gele Brug over het...

Continue reading

Deflamo AB: Deflamo AB:s (u.n.t Signatur Fastigheter AB) blivande dotterbolag SIG Invest AB förvärvar tre hyresfastigheter i Landskrona

SIG Invest AB förvärvar tre hyresfastigheter i Landskrona med en total uthyrningsbar yta om 3 618 kvm. Beståndet består av 45 lägenheter samt garage och parkeringsplatser.De bedömda hyresintäkterna uppgår till ca 3,7 miljoner kronor med ett bedömt driftnetto om 2,3 miljoner kronor.Överenskommet fastighetsvärde är 51 miljoner kronor. Förvärvet finansieras genom banklån och egna medel och tillträdet är beräknat till februari 2020.” Vi ser fram emot fler förvärv i Landskrona, som är en stad med goda utvecklingsmöjligheter. Det finns möjligheter att renovera lägenheter och utveckla vindar i dessa fastigheter vilket bidrar till vår tillväxt,” säger Dan Astrén, VD.BilagaPM Landskrona

Continue reading

Press Release Biocartis NV: Disclosure of a transparency notification

PRESS RELEASE: REGULATED INFORMATION12 December 2019, 07:00 CETDisclosure of a transparency notificationMechelen, Belgium, 12 December 2019 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that on 10 December 2019 it received a transparency notification dated 10 December 2019 (the ‘Notification’), indicating that on 6 December 2019 the shareholding of Sycomore Asset Management SA decreased below the 3% notification threshold. Sycomore Asset Management SA now holds 2.99% of the voting rights in Biocartis.The Notification contains...

Continue reading

Gantry Industrial Robots Market is Predicted to Reach USD 4.64 billion by 2026; Rapid Improvement in Production and Delivery Will Spur Demand for Industrial Robots, says Fortune Business Insights

Pune, Dec. 12, 2019 (GLOBE NEWSWIRE) — The global Gantry Industrial Robots Market size is expected to reach USD 4.64 billion by 2026, exhibiting a CAGR of 8.9% during the forecast period.  One of the factors encouraging the growth of the market is the ongoing automation in industries and production processes. The rapid improvement in production and delivery with the help of industrial robots will fuel demand among industries. In addition, increasing operational applications of gantry robots due to their advantages in the manufacturing process and material handling for many industries will further create opportunities for the market.As per the report, published by Fortune Business Insights, titled “Gantry Industrial Robots Market Size, Share & Industry Analysis, By Type (1-Axis, 2-Axis, 3-Axis, 4-Axis, & Others), By Application...

Continue reading

Athenex 宣佈將於 2019 年 12 月 13 日在 SABCS 舉行的投資者活動和網絡廣播的詳細資訊

美國紐約州水牛城, Dec. 12, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX) 作為一家致力於發現、開發和商業化用於治療癌症和相關疾病新型療法的全球性生物製藥公司,今天向投資界宣佈即將舉行的活動詳情,而該活動將在 2019 年聖安東尼奧乳癌專題討論會(SABCS)上發表口述匯報之後進行。活動亦將透過網絡直播,以供無法親自參與的人觀賞。活動將以臨床專家的演講為重點,臨床專家將在當天較早時 SABCS 上展示和審核科學會議的結果,題目為「口服紫杉醇併用 Encequidar:證實首個口服紫杉醇的反應和生存率優勝於 IV 紫杉醇,且神經病變較少:轉移性乳癌的第三期臨床研究。」 Athenex 的管理團隊成員也將出席討論研究結果。與會臨床專家醫學博士 Hope S. Rugo:Rugo 博士是 UCSF Helen Diller 家庭綜合癌症中心的醫學教授兼乳腺癌與臨床試驗教育主任。她是多項臨床試驗的主要研究員,致力於將新型標靶治療與標準治療結合,以改善早期和晚期的乳癌治療,且多次在相關領域發表文獻。她目前的研究興趣包括免疫療法和標靶藥物組合治療乳腺癌,旨在克服耐藥性。Rugo 博士是 Triple Negative 工作組的聯合主席和轉化型乳腺癌研究協會(TBCRC)的活躍成員,也是 TBCRC 轄下多項試驗的主要研究員,其中包括由乳腺癌研究基金會資助的一項多中心免疫療法試驗 (BCRF)。她是 Alliance(前稱 CALGB)乳房委員會以及 ASCO 的活躍成員,擔任其指導委員會成員,以及教育委員會編輯。Rugo 博士畢業於美國賓夕法尼亞大學醫學院。醫學博士 Gerardo Antonio Umanzor:Umanzor 博士是 洪都拉斯 Liga Contra el Cáncer 的醫學腫瘤學家和導師。Liga Contra el Cáncer 是洪都拉斯成立的非牟利非政府組織,是唯一為貧困人口提供優質醫療服務的組織,費用很低甚至免費。Umanzor...

Continue reading

Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock

MENLO PARK, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) — Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 4,860,000 shares of its common stock at a price to the public of $35.00 per share.  Gross proceeds to Forty Seven from the offering are expected to be $170.1 million, before deducting underwriting discounts and commissions and estimated offering expenses.  All of the shares of common stock are being offered by Forty Seven. In addition, Forty Seven has granted the underwriters a 30-day option to purchase up to 729,000 of additional shares of common stock at the public offering price, less underwriting discounts and commissions.  The offering is expected to close on December 16, 2019, subject to customary closing conditions.Morgan...

Continue reading

Livongo Announces Pricing of Public Offering by Selling Stockholders

MOUNTAIN VIEW, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) — Livongo Health, Inc. (Nasdaq: LVGO) today announced the pricing of its underwritten public offering of 2,777,327 shares of its common stock by certain selling stockholders at a price of $27.00 per share. Such selling stockholders have also granted the underwriters a 30-day option to purchase up to an additional 416,598 shares of common stock at the public offering price, less underwriting discounts and commissions. Livongo will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling stockholders, and will bear the costs associated with the sale of such shares, other than underwriting discounts and commissions.This offering is expected to close on or about December 16, 2019, subject to the satisfaction of customary closing...

Continue reading

CEMATRIX Corporation to host Investor Webcast on December 17, 2019

CALGARY, Alberta, Dec. 11, 2019 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSXV: CVX) (the “Corporation”) today announced that it will host a webcast investor presentation on Tuesday, December 17, at 11:00 AM ET.During the webcast, Jeff Kendrick – President and Chief Executive Officer, will provide an introductory presentation through a PowerPoint discussion that will cover key areas of CEMATRIX’s business, including industry overview, business verticals, technology summary, growth strategy and its scaling opportunity.  During parts of the presentation, investors will have an opportunity to ask relevant questions and interact with management through an interactive Q & A portal.To listen to the webcast or to ask questions during the live event, please pre-register at the following link: https://event.webcasts.com/starthere.jsp?ei=1271471&tp_key=9864e31654An...

Continue reading

Dentsply Sirona Declares Quarterly Cash Dividend

CHARLOTTE, N.C., Dec. 11, 2019 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (NASDAQ: XRAY), The Dental Solutions Company™, announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share of common stock, an indicated annual rate of $0.40 per share.  The dividend is payable on January 10, 2020 to holders of record on December 27, 2019.About Dentsply Sirona:Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide.  Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands.  As The Dental Solutions...

Continue reading

InterDigital Joins MulteFire Alliance Board Of Directors

WILMINGTON, Del., Dec. 11, 2019 (GLOBE NEWSWIRE) — InterDigital, Inc. (NASDAQ:IDCC), a mobile and video technology research and development company, today announced the appointment of two of its employees to the Board of Directors of MulteFire Alliance, an international consortium that advocates for the broad adoption of next generation mobile technologies in environments that use unlicensed and shared radio spectrum.MulteFire Alliance’s members have elected InterDigital’s Senior Director of Labs, Doug Castor, and Technical Staff Member, Muhammad Fazili, to serve as Full Director and Alternate Full Director, respectively. As representatives of InterDigital, the new directors will join board members from across the wireless technology industry, including representatives from Boingo, CableLabs, Ericsson, Huawei, Intel, Nokia, and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.